Patents Assigned to Nanospectra Biosciences, Inc.
-
Patent number: 10993769Abstract: Various methods, systems, and devices for treating tissue ablation are disclosed. Some embodiments disclosed herein pertain to methods of treating tumors, systems used for irradiating tissue and tumors with electromagnetic radiation, components and devices of that system, and kits for providing systems used for irradiating tissue and tumors with electromagnetic radiation. In some embodiments, the system provides sub-ablative infrared radiation that is absorbed by nanoparticles. In some embodiments, the nanoparticles absorb the radiation converting it into heat energy. In some embodiments, though the infrared radiation itself may be sub-ablative, the heat energy generated by the nanoparticles is sufficient to cause thermal coagulation, hyperthermia, and/or tissue ablation.Type: GrantFiled: January 17, 2020Date of Patent: May 4, 2021Assignee: Nanospectra Biosciences, Inc.Inventors: Glenn Patrick Goodrich, Jon Alexander Schwartz, Andrew Mark Murphy
-
Patent number: 10568693Abstract: Various methods, systems, and devices for treating tissue ablation are disclosed. Some embodiments disclosed herein pertain to methods of treating tumors, systems used for irradiating tissue and tumors with electromagnetic radiation, components and devices of that system, and kits for providing systems used for irradiating tissue and tumors with electromagnetic radiation. In some embodiments, the system provides sub-ablative infrared radiation that is absorbed by nanoparticles. In some embodiments, the nanoparticles absorb the radiation converting it into heat energy. In some embodiments, though the infrared radiation itself may be sub-ablative, the heat energy generated by the nanoparticles is sufficient to cause thermal coagulation, hyperthermia, and/or tissue ablation.Type: GrantFiled: December 14, 2017Date of Patent: February 25, 2020Assignee: Nanospectra Biosciences, Inc.Inventors: Glenn Patrick Goodrich, Jon Alexander Schwartz, Andrew Mark Murphy
-
Patent number: 9211419Abstract: Methods are provided for the treatment of diseases and disorders using systematically-introduced nanoparticles to create a focused localized hyperthermia in a target area to enhance the effect of additional treatment therapies such as ionizing radiation. Advantages include an enhancement of the therapeutic effect of other therapies by increasing perfusion or reducing hypoxia in the treatment area, further, the methods herein may also result in the disruption of the vasculature, which provide further impetus for such treatments, singly and in combination with conventional therapies such as chemotherapy and radiation therapy.Type: GrantFiled: January 16, 2013Date of Patent: December 15, 2015Assignees: Nanospectra Biosciences, Inc., Board of Regents, The University of Texas SystemInventors: Sunil Krishnan, Parmeswaran Diagaradjane, Jon Alexander Schwartz, James Chunjay Wang
-
Publication number: 20130225901Abstract: A method for the design, manufacturing, and use of a high-Z particle to enhance the effects of ionizing radiation. In particular, the use of a targeting molecule to enable cellular uptake by the target cells (tumor cells or endothelial cells proximate to the tumor) will enhance the dose effect.Type: ApplicationFiled: April 5, 2011Publication date: August 29, 2013Applicant: NANOSPECTRA BIOSCIENCES, INC.Inventors: Sunil Krishnan, Parmeswaran Diagaradjane, Glenn P. Goodrich, J. Donald Payne
-
Publication number: 20130197295Abstract: Methods are provided for the treatment of diseases and disorders using systematically-introduced nanoparticles to create a focused localized hyperthermia in a target area to enhance the effect of additional treatment therapies such as ionizing radiation. Advantages include an enhancement of the therapeutic effect of other therapies by increasing perfusion or reducing hypoxia in the treatment area, further, the methods herein may also result in the disruption of the vasculature, which provide further impetus for such treatments, singly and in combination with conventional therapies such as chemotherapy and radiation therapy.Type: ApplicationFiled: January 16, 2013Publication date: August 1, 2013Applicants: The Board of Regents of the University of Texas System, Nanospectra Biosciences, Inc.Inventors: Sunil Krishnan, Parmeswaran Diagaradjane, Jon Alexander Schwartz, James Chunjay Wang
-
Patent number: 8057418Abstract: Methods and devices are provided for the extracorporeal ablation of target cells circulating in blood of an organism. Exogenous material introduced into the blood preferentially associates with target cells (e.g. cancer cells, bacteria, viruses) in the blood. An extracorporeal continuous flow pathway accesses the patient's blood to apply an external energy source to the blood at an ex vivo ablation device in a portion of the extracorporeal continuous flow pathway. The exogenous material interact with the applied energy so as to result in the damage or death of the target cells. The blood is then returned to the body in a continuous-flow pattern. By applying the energy while the blood is in the ex vivo ablation device, shielding of the target cells by the body is reduced and detrimental effects on the organs and tissues of the body are avoided or mitigated.Type: GrantFiled: February 29, 2008Date of Patent: November 15, 2011Assignee: Nanospectra Biosciences, Inc.Inventors: Martin Korbling, J. Donald Payne, Christopher L. Coleman, Jon A. Schwartz
-
Patent number: 7438411Abstract: A contact lens is provided in which tunable nanoparticles are embedded or otherwise coated on the lens to extinguish near-infrared energy. In one preferred embodiment, the tunable nanoparticles are nanoshells consisting of a dielectric core and a metal shell, wherein the plasmon resonance frequency is determined by the relative size of the core and the metal shell. With the capability to alter the relative size of the core and the metal shell, nanoshells are uniquely tunable nanoparticles, allowing a range of optical extinctions. In another embodiment, the nanoshells are tuned to extinguish energy from other parts of the energy spectrum. In one desired embodiment of the invention, these plasmon resonant structures are introduced into the lens polymer prior to formation or manufacturing of a lens. In another embodiment of the invention, these nanoshells are coated on a contact lens after formation of the lens.Type: GrantFiled: May 5, 2006Date of Patent: October 21, 2008Assignee: Nanospectra Biosciences, Inc.Inventors: J. Donald Payne, Joseph B. Jackson